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Immunohistochemical and molecular markers in urothelial carcinoma
Urothelial carcinomas (UCs) are the second most common cancer of the genitourinary tract preceded by prostate carcinoma. It ranks fourth among men and eighth among women. They can present in an advanced stage invading the detrusor muscle or maybe superficial or nonmuscle invasive being confined to the mucosa or lamina propria. About 80% UCs are superficial and 70% recur after resection. [1] Multifocality is common leading to recurrence. Carcinomas "in situ" although nonmuscle invasive are more aggressive requiring excessive monitoring.
Since 2004, the WHO/ISUP 1998 classification has been used for the grading of bladder neoplasms. The newly described noninvasive urothelial lesions include urothelial dysplasia and urothelial proliferation of uncertain malignant potential (UPUMP). UPUMP is noticed in patients a lateral extension, i.e., "shoulder lesion" of papillary neoplasm as termed. [2, 3] Noninvasive tumors can be divided into two categories: papillary or flat. Flat ones include a wide spectrum ranging from reactive to preneoplastic to frankly malignant lesions. Papillary tumors include reactive proliferations, papilloma, and papillary urothelial proliferation of low malignant potential (PUNLMP) and low (LGPUC) and high grade (HGPUC) papillary carcinomas.
Histological grade has great significance in noninvasive lesions, especially the papillary types. Recurrence and progression are influenced by the pattern of growth, grade, dimension, multifocality, time of recurrence, and any prior bladder therapy. Grading can be subjective and so immunohistochemistry or molecular tests play a great role. Immunohistochemical markers serve as additional criteria in risk stratification of patients with noninvasive UC. Early lesions are associated with recurrence only when there is involvement of the lamina propria. [1] It is required that invasive UC should mention the percentage and types of divergent morphology in the histopathology report. [2, 4] For urinary neoplasias, currently, the most frequent problem relates to the classification of noninvasive lesions, especially separating PUNLMP from
LGPUC. [5] The only criteria available for differentiating these tumors are the degree of anaplasia or dysplasia. This distinction carries importance for the urologists in terms of tumor recurrence and progression. Clinical and morphological parameters, namely, size, grade, multifocality, and carcinoma "in situ" in the adjacent mucosa carry different clinical management. Some markers to correlate with the histologic grade, progression, clinical staging, and recurrence of UC include p53, Ki-67, and cytokeratin (CK20). p53 has been associated with recurrence, tumor progression, and metastasis-free interval. Mutation in p53 has a major role in the pathogenesis of urothelial tumors but is not the only step in carcinogenesis. It, however, has a role in the progression of PUNLMP to LGPUC. [5, 6] The expression of Ki-67 in the normal urothelium is low and restricted to the basal layers only. It, however, varies with the histologic grade, clinical stage, and is associated with recurrence. Aberrant expression of CK20 distinguishes between PUNLMP and LGPUC besides predicting recurrence. p63 immunoreactivity does not express any difference between LGPUC and HGPUC or noninvasive papillary UC. On the contrary, highly significant relationship has been reported for pT1 and pT2 in terms of percentage of p53 staining. Studies on the role of p53 and p63 immune reactions in the differential diagnosis and prognosis of UC according to the pathological stage and histological grade of UC are still underway. When PUNLMP and LGPUC cannot be differentiated by morphology alone or in high-grade lesions, cytoplasmic and basal (aberrant) expression pattern of MUC1 is helpful. MUC1 is expressed in a normal pattern in areas of the urinary bladder not involved by neoplasia or even in areas of PUNLMP but displays aberrant expression in areas of LGPUC and HGPUC. MUC1 sends a signal to p53, thus inhibiting cell death. [5] Bladder tumors have diverse biological behaviors so should be stratified at a molecular level with a purpose to segregate those with poor prognosis and to formulate treatment plans for superficial tumors diagnosed by morphology alone. Increasing tumor grade and stage expresses copy number abnormalities, increased genomic instability, and loss of heterozygosity. Numerous oncogenes and tumor suppressor genes have been identified in invasive UC including TP53, RB1, PIK3CA, and HRAS. TERT mutations may not predict the clinical outcome but carry significant diagnostic importance. [7] Micropapillary variant (MPV) is more aggressive and carries a poor prognosis than the This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
